Aromasin Articles
Aromatase inhibitors may increase risk of heart disease in postmenopausal women with breast cancer
10 December 2010
Pfizer’s Aromasin little different to tamoxifen in disease progression for breast cancer patients
14 December 2009
Pfizer's Aromasin boosts DFS 11% in early breast cancer
22 December 2008
Pfizer
23 July 2007
Pfizer data indicates differences between steroidal and non-steroidal aromatase inhibitors
26 March 2007
Pfizer's Aromasin cuts relapse risk 56%
22 December 2006
Strong data for AstraZeneca's Faslodex
22 December 2006
Aromatase inhibitors approved by UK's NICE
27 November 2006
UK's NICE gives AI's tentative approval
29 May 2006
Faslodex as advanced breast cancer drug
13 March 2006
Expanded indication for Pfizer's Aromasin
19 September 2005
Aromasin prolongs breast cancer survival
29 March 2004
Ipsen links with Pfizer in breast cancer trials
29 March 2004
Pharmacia EPS up by 8% in 2nd-quarter
29 July 2002
Pharmacia reveals new anticancer results
16 October 2000
Pharmacia completes Spanish restructuring
19 July 2000
US launch for P&U's Aromasin
27 January 2000
P&U continues turnaround, looking for 1999 double-digit growth
29 October 1999
P&U's Aromasin approved by FDA
28 October 1999
Aromasin cuts mortality in breast cancer
20 May 1999
New product line up at Pharmacia & Upjohn
16 April 1999
P&U Completes Trials With Tolterodine
16 December 1996
P&U Moves To Revamp Inherited Pipeline
3 June 1996
Pharmacia Pipeline Promises Future Growth
20 March 1995
Showing 1-36 of 36 articles
- 1
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- New study shows UCB's Neupro reduces NSBP in RLS patient
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
